{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {},
   "outputs": [],
   "source": [
    "from collections import defaultdict\n",
    "import os\n",
    "\n",
    "# Custom module imports\n",
    "from ehr import HealthRecord\n",
    "import utils\n",
    "\n",
    "# Visualization imports\n",
    "import matplotlib.pyplot as plt\n",
    "import seaborn as sns\n",
    "sns.set_style('whitegrid')\n",
    "\n",
    "# Spacy imports\n",
    "import scispacy\n",
    "from spacy import displacy\n",
    "import en_ner_bc5cdr_md\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "metadata": {},
   "outputs": [],
   "source": [
    "DATA_DIR = './n2c2_2018/train/'\n",
    "\n",
    "# Get all the file IDs\n",
    "file_ids = sorted(list(set(['.'.join(fname.split('.')[:-1]) for fname in os.listdir(DATA_DIR)])))\n",
    "\n"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### EDA"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "metadata": {},
   "outputs": [],
   "source": [
    "tags = []\n",
    "data = []\n",
    "\n",
    "for fid in file_ids:\n",
    "    record = HealthRecord(fid, text_path = DATA_DIR + fid + '.txt', \n",
    "                          ann_path = DATA_DIR + fid + '.ann')\n",
    "    tags.append(record.get_annotations())\n",
    "    data.append(record)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "\n",
       "ID: T1\n",
       "Entity name: Reason\n",
       "Character range: 10179 10197\n",
       "Entity text: 'recurrent seizures'"
      ]
     },
     "execution_count": 9,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# Entity example\n",
    "data[0].entities['T1']\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "\n",
       "ID: R1\n",
       "Relation type: Reason-Drug\n",
       "\n",
       "Entity 1: \n",
       "\n",
       "ID: T1\n",
       "Entity name: Reason\n",
       "Character range: 10179 10197\n",
       "Entity text: 'recurrent seizures'\n",
       "\n",
       "Entity 2: \n",
       "\n",
       "ID: T3\n",
       "Entity name: Drug\n",
       "Character range: 10227 10233\n",
       "Entity text: 'ativan'"
      ]
     },
     "execution_count": 10,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# Relation example\n",
    "data[0].relations['R1']\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Getting counts for different entities\n",
    "entity_counts = defaultdict(int)\n",
    "\n",
    "for entity_dict in tags:\n",
    "    for key, value in entity_dict['entities'].items():\n",
    "        entity_counts[value.name] += 1\n",
    "        \n",
    "# Convert defaultdict to dict\n",
    "entity_counts = dict(entity_counts)\n",
    "\n",
    "# Sort by value\n",
    "entity_counts = {key: value for key, value in sorted(entity_counts.items(), \n",
    "                                                     key = lambda x: x[1], \n",
    "                                                     reverse = True)}"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Gettings counts for different relations\n",
    "relation_counts = defaultdict(int)\n",
    "\n",
    "for entity_dict in tags:\n",
    "    for key, value in entity_dict['relations'].items():\n",
    "        relation_counts[value.name] += 1\n",
    "        \n",
    "# Convert defaultdict to dict\n",
    "relation_counts = dict(relation_counts)\n",
    "\n",
    "# Sort by value\n",
    "relation_counts = {key: value for key, value in sorted(relation_counts.items(), \n",
    "                                                       key = lambda x: x[1],\n",
    "                                                       reverse = True)}\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 14,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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\n",
      "text/plain": [
       "<Figure size 720x432 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "plt.figure(figsize = (10, 6))\n",
    "\n",
    "sns.barplot(x = list(entity_counts.keys()), y = list(entity_counts.values()), \n",
    "            palette = sns.light_palette(\"green\", n_colors = 10, reverse = True))\n",
    "\n",
    "# Annotating counts\n",
    "for i in range(len(entity_counts.values())):\n",
    "    plt.text(x = i - 0.2, y = list(entity_counts.values())[i] + 40, \n",
    "             s = list(entity_counts.values())[i])\n",
    "    \n",
    "# Setting plot title\n",
    "plt.title('Number of occurences of each entity over 303 EHR records', fontsize = 15)\n",
    "plt.savefig('./plots/entity_counts.jpg')\n",
    "plt.show()\n",
    "\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 15,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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\n",
      "text/plain": [
       "<Figure size 864x432 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "plt.figure(figsize = (12, 6))\n",
    "\n",
    "sns.barplot(x = list(relation_counts.keys()), y = list(relation_counts.values()), \n",
    "            palette = sns.light_palette(\"green\", n_colors = 10, reverse = True))\n",
    "\n",
    "plt.ylim(0, 8000)\n",
    "\n",
    "# Annotating counts\n",
    "for i in range(len(relation_counts.values())):\n",
    "    plt.text(x = i - 0.2, y = list(relation_counts.values())[i] + 40, \n",
    "             s = list(relation_counts.values())[i])\n",
    "    \n",
    "# Setting plot title\n",
    "plt.title('Number of occurences of entity-relationships over 303 EHR records', fontsize = 15)\n",
    "plt.savefig('./plots/relation_counts.jpg')\n",
    "plt.show()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 16,
   "metadata": {},
   "outputs": [],
   "source": [
    "nlp = en_ner_bc5cdr_md.load()\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 17,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Admission Date:  [**2115-2-22**]              Discharge Date:   [**2115-3-19**]</br></br>Date of Birth:  [**2078-8-9**]             Sex:   M</br></br>Service: MEDICINE</br></br>\n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Allergies\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       ":</br>Vicodin</br></br>Attending:[**First Name3 (LF) 4891**]</br>Chief Complaint:</br>\n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Post-cardiac arrest\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       ", \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    asthma\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " exacerbation</br></br>Major Surgical or Invasive Procedure:</br>Intubation</br>Removal of chest tubes placed at an outside hospital</br>R CVL placement</br></br></br>History of Present Illness:</br>Mr. [**Known lastname 3234**] is a 36 year old gentleman with a PMH signifciant</br>with \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    dilated cardiomyopathy\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " s/p AICD, \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    asthma\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       ", and \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    HTN\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " admitted</br>to an OSH with \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    dyspnea\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " now admitted to the MICU after \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    PEA arrest\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       "</br>x2. The patient initially presented to LGH ED with \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    hypoxemic\n",
       "respiratory distress\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       ". While at the OSH, he received CTX,</br>\n",
       "<mark class=\"entity\" style=\"background: #F9E79F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    azithromycin\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       ", SC \n",
       "<mark class=\"entity\" style=\"background: #F9E79F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    epinephrine\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       ", and \n",
       "<mark class=\"entity\" style=\"background: #F9E79F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    solumedrol\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       ". While at the OSH,</br>he became confused and subsequently had an episode of \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    PEA arrest\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       "</br>and was intubated. He received \n",
       "<mark class=\"entity\" style=\"background: #F9E79F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    epinephrine\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       ", \n",
       "<mark class=\"entity\" style=\"background: #F9E79F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    atropine\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       ", \n",
       "<mark class=\"entity\" style=\"background: #F9E79F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    magnesium\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       ",</br>and bicarb. In addition, he had bilateral needle thoracostomies</br>with report of air return on the left, and he subsequently had</br>bilateral chest tubes placed.  After approximately 15-20 minutes</br>of rescucitation, he had ROSC. He received \n",
       "<mark class=\"entity\" style=\"background: #F9E79F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    vecuronium\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       " and was</br>started on an epi gtt for \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    asthma\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " and a cooling protocol, and was</br>then transferred to [**Hospital1 18**] for further evaluation. Of note, the</br>patient was admitted to LGH in [**1-4**] for \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    dyspnea\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       ", and was</br>subsequently diagnosed with a \n",
       "<mark class=\"entity\" style=\"background: #F9E79F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    CAP\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       " and \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    asthma\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " treated with CTX</br>and \n",
       "<mark class=\"entity\" style=\"background: #F9E79F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    azithromycin\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       ". Per his family, he has also had multiple</br>admissions this winter for \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    asthma\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " exacerbations.</br>.</br>In the [**Hospital1 18**] ED, 35.3 102 133/58 100%AC 500x20, 5, 1.0 with an</br>ABG 7.16/66/162. He had a CTH which was unremarkable. He then</br>had a CTA chest, \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    afterwhich\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " he went into \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    PEA arrest\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       ".</br>Rescucitation last approximately 10-15 minutes with multiple</br>rounds of epi and bicarb, with ROSC. He was then admitted to the</br>MICU for further management.</br>.</br>Currently, the patient is intubated, sedated, and parlyzed.</br></br>Past Medical History:</br>Asthma</br>\n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Dilated cardiomyopathy\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       "</br>Multiple admissions for \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    dyspnea\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " this winter ([**1-26**]).</br>Anxiety/depression</br>\n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    CKD\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       "</br>\n",
       "<mark class=\"entity\" style=\"background: #F9E79F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    HLD\n",
       "Obesity\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       "</br>\n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    HTN\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       "</br></br>Social History:</br>Unknown</br></br>Family History:</br>Unknown</br></br>Physical Exam:</br>ADMISSION:</br>VS: 35.9 124 129/67 99% AC 480x24, 5, 1.0</br>Gen: ETT in place, intubated, sedated.</br>HEENT: ETT in place.</br>CV: Tachy S1+S2</br>Pulm: Poor air movement bilaterally. Diffuse wheezes</br>bilaterally.</br>Abd: S/D hypoactive BS</br>Ext: 1+ \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    edema\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " bilaterally</br>Neuro: Unresponsive.</br>.</br>Discharge: 98.5 102/65 76 20 95-98% \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    RA\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       "</br>In cage bed to prevent patient from falling out of bed.</br>Occasionally calling out. Lungs clear without wheezes.</br></br></br>Pertinent Results:</br>Labs on Admission:</br>[**2115-2-22**] 08:50AM BLOOD WBC-19.5* RBC-4.76 Hgb-14.9 Hct-44.3</br>MCV-93 MCH-31.4 MCHC-33.7 RDW-12.9 Plt Ct-201</br>[**2115-2-22**] 08:50AM BLOOD PT-14.1* PTT-25.9 INR(PT)-1.2*</br>[**2115-2-22**] 08:50AM BLOOD Glucose-306* UreaN-21* Creat-1.2 Na-144</br>K-4.1 Cl-111* HCO3-28 \n",
       "<mark class=\"entity\" style=\"background: #F9E79F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    AnGap-9\n",
       "\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       "[**2115-2-22**] 08:50AM BLOOD Albumin-3.4* Calcium-6.2* Phos-5.5*</br>Mg-2.2</br>[**2115-2-22**] 09:32AM BLOOD calTIBC-320 Ferritn-1129* TRF-246</br>[**2115-2-22**] 07:17AM BLOOD Type-ART pO2-162* pCO2-66* pH-7.16*</br>calTCO2-25 Base XS--6 Intubat-INTUBATED</br>.</br>Labs on Discharge</br>[**2115-3-18**] 11:34AM BLOOD Type-ART pO2-95 pCO2-33* pH-7.54*</br>calTCO2-29 Base XS-5 Intubat-NOT INTUBA</br>[**2115-3-5**] 05:35AM BLOOD ALT-49* AST-23 AlkPhos-53 TotBili-0.9</br>[**2115-3-19**] 04:45AM BLOOD Glucose-73 UreaN-25* Creat-1.4* Na-133</br>K-4.1 Cl-95* HCO3-21* AnGap-21*</br>[**2115-3-19**] 04:45AM BLOOD WBC-12.4* RBC-4.47* Hgb-14.3 Hct-41.3</br>MCV-93 MCH-32.0 MCHC-34.6 RDW-13.3 Plt Ct-352</br>[**2115-3-19**] 04:45AM BLOOD Neuts-56 Bands-0 Lymphs-38 Monos-3 Eos-3</br>Baso-0 Atyps-0 \n",
       "<mark class=\"entity\" style=\"background: #F9E79F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Metas-0\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       " Myelos-0</br>.</br>CXR (in MICU): Mr read - \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    cardiomegaly\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       ", RIJ in SVC, ETT 4.5 cm</br>above carina. Blunting of costophrenic angles bilaterally with</br>low lung volumes. Loss of retrocardiac diagphragm and bilateral</br>opacities (L&gt;R)</br>.</br>CXR:</br>1. \n",
       "<mark class=\"entity\" style=\"background: #F9E79F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    NG\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       " tube at 7.2 cm above the carina. [**Month (only) 116**] consider advancing</br>for optimal placement.</br>2. Severe \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    cardiomegaly\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " with globular shape. In the absence of</br>prior</br>comparison, the differential is broad, including moderate</br>pericardial</br>effusion, \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    mediastinal hemorrhage\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       ", or \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    acute cardiac failure\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       ".</br>Recommend</br>clinical correlation.</br>.</br>CTH: My read, no acute bleed</br>.</br>CTA Chest:</br>1. No evidence of \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    pulmonary embolism\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       ", although evaluation of</br>subsegmental branches is limited.</br>2. Moderate \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    cardiomegaly\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " without \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    pericardial effusion\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       ".</br>3. Bilateral dependent \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    atelectasis\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       ".</br>4. Multiple nondisplaced rib \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    fractures\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " on the right, some of</br>which are subacute. Also possible subtle nondisplaced \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    fractures\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       "</br>of the left ribs.</br>5. Nondisplaced \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    acute sternal fracture\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " in addition to a subacute</br>nondisplaced sternal fracture.</br>.</br>TTE: The left atrium is moderately dilated. The estimated right</br>atrial pressure is 10-20mmHg. Left ventricular wall thicknesses</br>are normal. The left ventricular cavity is severely dilated. LV</br>systolic function appears \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    depressed\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " (ejection fraction ? 30</br>percent) with regional variation. There is considerable</br>beat-to-beat variability of the left ventricular ejection</br>fraction due to an irregular rhythm/premature beats. The right</br>ventricular free wall thickness is normal. The right ventricular</br>cavity is dilated with \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    depressed\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " free wall contractility. The</br>aortic root is mildly dilated at the sinus level. The ascending</br>aorta is mildly dilated. The aortic valve leaflets (3) appear</br>structurally normal with good leaflet excursion and no aortic</br>\n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    stenosis\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " or \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    aortic regurgitation\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       ". The mitral valve leaflets are</br>structurally normal. There is no \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    mitral valve prolapse\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       ". Mild</br>(1+) \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    mitral regurgitation\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " is seen. The pulmonary artery systolic</br>pressure could not be determined. There is no pericardial</br>effusion.</br>.</br>ECG (post-arrest):  Sinus with 1:1 conduction. LAA. LAD, RBBB,</br>LAFB. STD in V4-V6.</br>.</br>ECG (pre-arrest): Sinus with 1:1 conduction. LAD, bifascicular</br>block. No lateral STD.</br>.</br>ECG (OSH, unclear pre/post arrest): Sinus with 1:1 conduction.</br>Bifascicular (RBBB, LAFB) block. STD in V5-6.</br>.</br>EEG [**2-27**]</br>IMPRESSION: This is an abnormal video EEG telemetry due to the</br>slow and</br>disorganized background of 6.5 Hz with bursts of generalized</br>slowing</br>that showed no clear reactivity. These findings indicate a</br>severe</br>\n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    encephalopathy\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       ". This may be consistent with the patient's</br>history of</br>\n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    anoxia\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       "; however, \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    toxic/metabolic disturbances\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       ", \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    infection\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       ", and</br>medication</br>effects are also among the most frequent causes of</br>\n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    encephalopathy\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       ". No</br>clear epileptiform discharges or \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    seizures\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " were seen.</br></br>LUMBAR SPINE [**2115-3-11**]</br></br>CLINICAL INFORMATION: Evidence of \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    fracture\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       ", \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    seizure\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       ", fall, low</br>\n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    back pain\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       ".</br></br>FINDINGS:</br></br>Three views of the lumbar spine demonstrate mild narrowing of</br>the left</br>femoroacetabular joint. There is mild \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    scoliosis\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " of the</br>thoracolumbar spine.  The ventricular lead of a pacemaker is</br>identified. No \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    fracture\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " of L2 through L5 is identified. However,</br>there is a compression \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    fracture\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " of L1, with compression of the</br>superior endplate, and a sclerotic \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    fracture\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " line. Given the</br>mechanism of fall, if there is \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    acute pain\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " referable to L1, then</br>this would be considered an acute finding. There is no apparent</br>retropulsion of the posterior margin of L1 into the spinal</br>canal. No other \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    fractures\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " are identified at this time. Facet</br>joints are aligned. There is early \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    calcification of the aorta\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       ".</br>IMPRESSION: \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Compression fracture\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " of L1 with anterior wedge</br>\n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    deformity\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       ", likely an acute finding. No other \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    fractures\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       "</br>identified.</br>EKG: Normal sinus rhythm. Complete right bundle-branch block</br>with left anterior fascicular block. Diffuse ST-T wave changes</br>laterally.</br>CT Head:</br>COMPARISON: [**2115-2-22**].</br>TECHNIQUE: Non-contrast axial images were obtained through the</br>brain.</br>FINDINGS: There is no \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    intracranial hemorrhage\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       ", \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    edema\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       ", or \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    loss of\n",
       "[*\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       "*Doctor Last Name 352**]/white matter differentiation. Ventricles and sulci are</br>normal in size and configuration. The basilar cisterns are not</br>compressed. Paranasal sinuses demonstrate fluid in the sphenoid</br>air cells and right posterior ethmoid air cell, likely related</br>to prolonged hospitalization.  Mastoid air cells are well</br>aerated.</br>IMPRESSION: No evidence of acute \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    intracranial abnormalities\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       ".</br></br></br>Brief Hospital Course:</br>Mr. [**Known lastname 3234**] is a 36 year old gentleman with a PMH signifciant</br>with \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    dilated cardiomyopathy\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " s/p AICD, \n",
       "<mark class=\"entity\" style=\"background: #F9E79F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    PE\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       " not on anticoagulation,</br>\n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    asthma\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       ", and \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    HTN\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " admitted to an OSH with \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    dyspnea\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " now the</br>transferred to [**Hospital1 18**] MICU after PEA arrest x2.</br></br># \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    PEA arrest\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " and subsequent \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    anoxic brain injury\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       ".: Suspect that</br>original OSH \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    PEA arrest\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " due to \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    hypoxemia\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " or \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    acidosis\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       ", with [**Hospital1 18**]</br>ED \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    PEA arrest\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " due to \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    acidosis\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " with admission pH 7.16 on arrival.</br> TTE with evidence of \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    RV failure\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " to suggest \n",
       "<mark class=\"entity\" style=\"background: #F9E79F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    PE\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       ". LVEF 30% with</br>known \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    dilated cardiomyopathy\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       ". He was cooled per protocol.</br>Initially, his EEG was concerning without evident brain</br>activity. On hospital day 3, there was only \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    comatose\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " activity</br>and his prognosis was guarded. However, the patient was able to</br>be weaned off the vent and over the course of the next three</br>days his mental status improved.  He was alert, oriented to</br>place and day of the week and moving all 4 extremities.  He</br>became more interactive on transfer to the floor, was initially</br>speaking in spanish and English and not always making sense but</br>then started responding more appropiately and following</br>commands.  On hospital day 11 he had a witnessed grand mal</br>\n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    seizure\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " and was given ativan and started on Keppra with</br>neurology consult.  His mental status was worse for 24 hours</br>after the \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    seizure\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " but then he slowly returned to his recent</br>baseline.  He was somewhat aggitated so his Keppra was switched</br>to \n",
       "<mark class=\"entity\" style=\"background: #F9E79F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Topiramate\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       ". He had a subsequent \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    seizure\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " on [**3-18**] with LUE</br>tonic clonic activity and \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    impaired consciousness\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " but this</br>resolved spontaneously after 1-2 minutes. He was contineud on</br>topamax per neuro recommendations. \n",
       "<mark class=\"entity\" style=\"background: #F9E79F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    OT\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       " and PT were consulted and</br>worked with the patient as he will likely require a long</br>rehabilitation course.  At the time of discharge the patient was</br>alert, oriented (though not always to date), following commands</br>but impulsive with poor motor planning leading to several falls.</br> Neurology notes indicate the patient has the potential</br>toimprove from a neurologic standpoint. He also may have</br>recurrent \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    seizures\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " which should be treated with ativan IV or IM</br>and do not neccessarily indicate patient needs to return to</br>hospital unless they continue for greater than 5 minutes or he</br>has multiple recurrent \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    seizures\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " or complications such as</br>aspiration.</br>-patient will be on \n",
       "<mark class=\"entity\" style=\"background: #F9E79F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Topiramate\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       " 25mg PO BID until [**3-22**] PM then</br>increase to 50mg po BID for seven days then increase to 75mg [**Hospital1 **]</br>ongoing.</br>-patient will follow up with Dr. [**Last Name (STitle) **] [**Name (STitle) **] in his s/p</br>arrest neurology clinic</br>-patient will require intensive PT and \n",
       "<mark class=\"entity\" style=\"background: #F9E79F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    OT\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       " in an anoxic brain</br>injury unit.</br>.</br># \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Respiratory failure\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       ": Believed to be due to \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    status asthmaticus\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       ",</br>although inciting event unclear. [**Name2 (NI) 227**] multiple cardiac arrests,</br>also a concern for development of \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    ARDS\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       ".  The patient was</br>initially treated broadly with \n",
       "<mark class=\"entity\" style=\"background: #F9E79F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    vancomycin\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       ", \n",
       "<mark class=\"entity\" style=\"background: #F9E79F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    cefepime\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       ", flagyl,</br>cipro, and oseltamavir. He was treated with IV \n",
       "<mark class=\"entity\" style=\"background: #F9E79F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    soludemedrol\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       " and</br>\n",
       "<mark class=\"entity\" style=\"background: #F9E79F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    albuterol\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       " MDI. He was ventialted according to ARDS-Net protocol.</br>On admission, he had two chest tubes placed for \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    pneumothoraces\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       ".</br>They were removed on hospital day 1. In his first several days,</br>his respiratory status was \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    comprimised by lobar collapse\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       ", first</br>of the RUL and then of the \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    RML\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       ". His extubation was initially</br>limited both by \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    agitation\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " requiring sedation and by requirements</br>for high PEEP to maintain oxygenation. His oxygenation was</br>improved with diuresis and \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    agitation\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " was better controlled with</br>\n",
       "<mark class=\"entity\" style=\"background: #F9E79F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    seroquel\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       ". He was extubated on [**3-1**] and respiratory status was</br>stable.  His Asthma was treated with standing and PRN \n",
       "<mark class=\"entity\" style=\"background: #F9E79F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    albuterol\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       "</br>and \n",
       "<mark class=\"entity\" style=\"background: #F9E79F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    ipratriopium\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       " and a slow \n",
       "<mark class=\"entity\" style=\"background: #F9E79F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    prednisone\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       " taper which he l</br>completed on [**2115-3-18**] and he was restarted on Advair</br>-patient may require additional nebs on top of his standing</br>advair though his respiratory status has been very stable,</br>without \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    wheezing\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " for the last week.</br>- would like benefit from outpatient PFTs and is scheduled to</br>see a pulmonologist in follow up.</br>.</br># Ventilator associated \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    pneumonia\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       ":  Patient developed a \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    fever\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " on</br>[**2-27**] with new infiltrates on chest xray while intubated. He was</br>initially covered with vanc/cefepime and cipro. \n",
       "<mark class=\"entity\" style=\"background: #F9E79F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Cipro\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       " was</br>eventually discontinued. He did not grow any organisms other</br>than yeast in his sputum. He completed an 8 day course of</br>Vanco/Cefepime.</br>.</br># \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Myoclonus\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       ": when mental status improved, was noted to have</br>\n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    myoclonic jerks\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       ". per neurology, likely [**First Name8 (NamePattern2) **] [**Last Name (NamePattern1) 1683**] Syndrome</br>which is \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    anoxic injury\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " to the purkinje cells.  These \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    jerks\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       "</br>continued for about one week and then became rare.</br>.</br># dilated [**Last Name (LF) 89982**], [**First Name3 (LF) **] 30%. s/p ICD.  Patient was</br>diuresed with IV lasix in the ED and then transitioned to PO</br>lasix, home dose, on the floor.  His respiratory status remained</br>stable. Also continued on home dose of \n",
       "<mark class=\"entity\" style=\"background: #F9E79F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    carvedilol\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       " and \n",
       "<mark class=\"entity\" style=\"background: #F9E79F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Lisinopril\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       "</br>but ACE downtitrated from 40 to 20 when had elevated \n",
       "<mark class=\"entity\" style=\"background: #F9E79F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Cr\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       " 1.9 on</br>[**3-18**] and slightly low \n",
       "<mark class=\"entity\" style=\"background: #F9E79F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    BPs\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       " high 90s/60s. BP improved to 100s/60s.</br></br>.</br>#\n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Hypertension\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       ": Patient's home regimen was continued on the</br>floor, but his SBP dipped into the high 80s and low 90s so</br>\n",
       "<mark class=\"entity\" style=\"background: #F9E79F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    lisinopril\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       " was decreased to 20mg po daily and his SBP remained</br>100-130.</br>.</br># L1 compression \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    fracture\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       ": After the patient fell, he was</br>complaining of \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    low back pain\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " so a L-spine Xray was performed and</br>showed L1 \n",
       "<mark class=\"entity\" style=\"background: #F9E79F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    compressin fracture\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       " with No \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    cord impingement\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " on</br>imaging.  The patient had no localizing deficits on serial neuro</br>exam.  He was treated with \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    pain\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " medication including low dose</br>ultram, standing \n",
       "<mark class=\"entity\" style=\"background: #F9E79F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    tylenol\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       " and a \n",
       "<mark class=\"entity\" style=\"background: #F9E79F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    lidocaine\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       " patch.  \n",
       "<mark class=\"entity\" style=\"background: #F9E79F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Calcitonin\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       " was</br>tried for \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    pain\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " with \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    compression fracture\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " but this did not seem</br>to help with symptoms so was discontinued.</br>.</br># \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Leukocytosis\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       ": WBC &gt;20  persistently in the MICU even after</br>being treated for \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    infection\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       ".  Since no new \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    infection\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " was found</br>this was presumed [**12-26**] \n",
       "<mark class=\"entity\" style=\"background: #F9E79F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    steroids\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       " and the \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    leukocytosis\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " improved</br>with \n",
       "<mark class=\"entity\" style=\"background: #F9E79F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    prednisone\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       " taper.  WBC 12 on day of discharge</br>.</br># \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Hyperglycemia\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       ": Patient is not known to be a \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    diabetic\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " and was</br>felt [**12-26**] \n",
       "<mark class=\"entity\" style=\"background: #F9E79F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    steroids\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       ",  his \n",
       "<mark class=\"entity\" style=\"background: #F9E79F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    sugars\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       " were controlled on sliding scale</br>insulin in the hospital but he no longer had insulin</br>requirements as his \n",
       "<mark class=\"entity\" style=\"background: #F9E79F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    prednisone\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       " was tapered.</br>.</br>#. [**Last Name (un) **]: Cr 1.9 on [**3-18**] from 1.2 which improved to 1.4 on [**3-19**]</br>with decreasing ACE and 500cc bolus. He should have repeat</br>\n",
       "<mark class=\"entity\" style=\"background: #F9E79F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    creatinine\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       " and labs on [**3-22**] to ensure stability.</br></br># Guardianship: Guardianship paperwork was started in the</br>hospital.</br></br>Medications on Admission:</br>\n",
       "<mark class=\"entity\" style=\"background: #F9E79F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Carvedilol\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       " 25 [**Hospital1 **]</br>\n",
       "<mark class=\"entity\" style=\"background: #F9E79F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Lasix\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       " 80 mg po bid</br>\n",
       "<mark class=\"entity\" style=\"background: #F9E79F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Xanax\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       " 0.25 mg 1-2 tabs prn</br>\n",
       "<mark class=\"entity\" style=\"background: #F9E79F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    albuterol\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       " MDI</br>\n",
       "<mark class=\"entity\" style=\"background: #F9E79F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Ibuprofen\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       " prn</br>Benadryl prn</br>Advair diskus</br>Lsinopril 40 daily</br></br>Discharge Medications:</br>1. bisacodyl 5 mg Tablet, Delayed Release (E.C.) Sig: Two (2)</br>Tablet, Delayed Release (E.C.) PO DAILY (Daily) as needed for</br>\n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Constipation\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       ".</br>2. senna 8.6 mg Tablet Sig: One (1) Tablet PO BID (2 times a</br>day) as needed for \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Constipation\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       ".</br>3. \n",
       "<mark class=\"entity\" style=\"background: #F9E79F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    acetaminophen\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       " 325 mg Tablet Sig: Two (2) Tablet PO \n",
       "<mark class=\"entity\" style=\"background: #F9E79F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Q6H\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       " (every</br>6 hours) as needed for pain/fever.</br>4. \n",
       "<mark class=\"entity\" style=\"background: #F9E79F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    carvedilol\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       " 12.5 mg Tablet Sig: Two (2) Tablet PO BID (2 times</br>a day).</br>5. \n",
       "<mark class=\"entity\" style=\"background: #F9E79F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    docusate sodium\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       " 100 mg Capsule Sig: One (1) Capsule PO BID (2</br>times a day).</br>6. \n",
       "<mark class=\"entity\" style=\"background: #F9E79F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    furosemide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       " 40 mg Tablet Sig: Two (2) Tablet PO BID (2 times a</br>day).</br>7. \n",
       "<mark class=\"entity\" style=\"background: #F9E79F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    lisinopril\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       " 10 mg Tablet Sig: Two (2) Tablet PO DAILY (Daily).</br></br>8. \n",
       "<mark class=\"entity\" style=\"background: #F9E79F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    olanzapine\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       " 5 mg Tablet, Rapid \n",
       "<mark class=\"entity\" style=\"background: #F9E79F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Dissolve Sig\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       ": [**11-25**] Tablet, Rapid</br>Dissolves PO QHS (once a day (at bedtime)) as needed for sleep.</br></br>9. \n",
       "<mark class=\"entity\" style=\"background: #F9E79F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    calcium carbonate\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       " 200 mg (500 mg) Tablet, Chewable Sig: One</br>(1) Tablet, Chewable PO BID (2 times a day).</br>10. \n",
       "<mark class=\"entity\" style=\"background: #F9E79F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    cholecalciferol\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       " (\n",
       "<mark class=\"entity\" style=\"background: #F9E79F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    vitamin D3\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       ") 400 unit Tablet Sig: One (1)</br>Tablet PO DAILY (Daily).</br>11. \n",
       "<mark class=\"entity\" style=\"background: #F9E79F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    acetaminophen\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       " 500 mg Tablet Sig: Two (2) Tablet PO TID (3</br>times a day) as needed for pain/fever.</br>12. \n",
       "<mark class=\"entity\" style=\"background: #F9E79F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    lidocaine\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       " 5 %(700 mg/patch) Adhesive Patch, Medicated Sig:</br>One (1) Adhesive Patch, Medicated Topical DAILY (Daily): 12</br>hours on and 12 hours off every 24 hour period.</br>13. \n",
       "<mark class=\"entity\" style=\"background: #F9E79F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    ipratropium bromide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       " 0.02 % Solution Sig: One (1) neb</br>Inhalation every six (6) hours.</br>14. \n",
       "<mark class=\"entity\" style=\"background: #F9E79F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    albuterol sulfate\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       " 2.5 mg /3 mL (0.083 %) Solution for</br>Nebulization Sig: One (1) neb Inhalation every six (6) hours.</br>15. \n",
       "<mark class=\"entity\" style=\"background: #F9E79F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    albuterol sulfate\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       " 2.5 mg /3 mL (0.083 %) Solution for</br>Nebulization Sig: One (1) neb Inhalation Q2H (every 2 hours) as</br>needed for SOB.</br>16. \n",
       "<mark class=\"entity\" style=\"background: #F9E79F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    topiramate\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       " 25 mg Tablet Sig: One (1) Tablet PO BID (2 times</br>a day) for 3 days: 1 [**Hospital1 **] until [**3-22**] PM then increase to 2</br>tablets [**Hospital1 **] for 7 days then 3 tablets [**Hospital1 **] ongoing.</br>17. \n",
       "<mark class=\"entity\" style=\"background: #F9E79F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    tramadol\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       " 50 mg Tablet Sig: One (1) Tablet PO \n",
       "<mark class=\"entity\" style=\"background: #F9E79F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Q6H\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       " (every 6</br>hours) as needed for \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    back pain\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       ".</br>18. \n",
       "<mark class=\"entity\" style=\"background: #F9E79F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    fluticasone-salmeterol 250-50\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       " mcg/dose Disk with Device Sig:</br>One (1) inh Inhalation [**Hospital1 **] (2 times a day).</br>19. \n",
       "<mark class=\"entity\" style=\"background: #F9E79F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    lorazepam\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       " 2 mg/mL Syringe Sig: 1-2 mg Injection twice a day</br>as needed for \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    seizure\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " that last longer than 5 minutes.</br></br></br>Discharge Disposition:</br>Extended Care</br></br>Facility:</br>[**Hospital6 979**] - [**Location (un) 246**]</br></br>Discharge Diagnosis:</br>\n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Anoxic Brain Injury\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " s/p \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    PEA arrest\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " x2</br>Status Asthmaticus</br>Ventilator Associated \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Pneumonia\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       "</br>Chronic Systolic Heart Failure</br>L1 compression fracture</br>\n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Seizures\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " after \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    hypoxic brain injury\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       "</br></br></br>Discharge Condition:</br>Mental Status: Confused - sometimes.</br>Level of Consciousness: Alert and interactive.</br>Activity Status: Ambulatory - requires assistance or aid (walker</br>or cane) because he has poor motor planning</br></br></br>Discharge Instructions:</br>You came to the hospital after having a \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    cardiac arrest\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " and an</br>\n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    asthma\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " exacerbation.  You had another \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    cardiac arrest\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " in our</br>hospital and were admitted to the MICU.  You required intubation</br>but were able to wean off the machine and breathe on your own.</br>We treated you for \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    pneumonia\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " and \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    asthma\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       ".  Your mental status</br>slowly improved, though you did have 2 \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    seizures\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       ", last on [**3-18**].\n",
       "You were started ons eizure medications for this.\n",
       ".\n",
       "Please take your medications as prescribed and follow up with\n",
       "your doctors [**Name5 (PTitle) 7928**].\n",
       "\n",
       "Followup Instructions:\n",
       "Department: PULMONARY FUNCTION LAB\n",
       "When: WEDNESDAY [**2115-4-3**] at 1:10 PM\n",
       "With: PULMONARY FUNCTION LAB [**Telephone/Fax (1) 609**]\n",
       "Building: [**Hospital6 29**] [**Location (un) **]\n",
       "Campus: EAST     Best Parking: [**Hospital Ward Name 23**] Garage\n",
       "\n",
       "Department: MEDICAL SPECIALTIES\n",
       "When: WEDNESDAY [**2115-4-3**] at 1:30 PM\n",
       "With: DR [**Last Name (STitle) **]/DR [**Last Name (STitle) **] [**Telephone/Fax (1) 612**]\n",
       "Building: SC [**Hospital Ward Name 23**] Clinical Ctr [**Location (un) **]\n",
       "Campus: EAST     Best Parking: [**Hospital Ward Name 23**] Garage\n",
       "\n",
       "Department: COGNITIVE NEUROLOGY UNIT\n",
       "When: THURSDAY [**2115-4-11**] at 1 PM\n",
       "With: [**First Name11 (Name Pattern1) **] [**Last Name (NamePattern4) 6403**], MD [**Telephone/Fax (1) 1690**]\n",
       "Building: Ks [**Hospital Ward Name 860**] Building ([**Hospital Ward Name 1826**]/[**Hospital Ward Name 1827**] Complex) [**Location (un) **]\n",
       "Campus: EAST     Best Parking: Main Garage\n",
       "\n",
       "\n",
       "\n",
       "</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "doc = nlp(data[0].text)\n",
    "\n",
    "colors = {\"DISEASE\":\"#D7BDE2\", \"CHEMICAL\":\"#F9E79F\"}\n",
    "options = {\"ents\":[\"DISEASE\", \"CHEMICAL\"], \"colors\":colors}\n",
    "displacy.render(doc, style = \"ent\", jupyter=True, options = options)\n",
    "\n"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Custom-built entity highlighter"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 18,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<span style = \"background-color: #aa9cfc; border-radius: 5px;\">&nbsp;Drug&nbsp;</span>&nbsp&nbsp&nbsp&nbsp&nbsp<span style = \"background-color: #ff9561; border-radius: 5px;\">&nbsp;Strength&nbsp;</span>&nbsp&nbsp&nbsp&nbsp&nbsp<span style = \"background-color: #7aecec; border-radius: 5px;\">&nbsp;Form&nbsp;</span>&nbsp&nbsp&nbsp&nbsp&nbsp<span style = \"background-color: #9cc9cc; border-radius: 5px;\">&nbsp;Frequency&nbsp;</span>&nbsp&nbsp&nbsp&nbsp&nbsp<span style = \"background-color: #ffeb80; border-radius: 5px;\">&nbsp;Route&nbsp;</span>&nbsp&nbsp&nbsp&nbsp&nbsp<span style = \"background-color: #bfe1d9; border-radius: 5px;\">&nbsp;Dosage&nbsp;</span>&nbsp&nbsp&nbsp&nbsp&nbsp<span style = \"background-color: #e4e7d2; border-radius: 5px;\">&nbsp;Reason&nbsp;</span>&nbsp&nbsp&nbsp&nbsp&nbsp<span style = \"background-color: #ff8197; border-radius: 5px;\">&nbsp;ADE&nbsp;</span>&nbsp&nbsp&nbsp&nbsp&nbsp<span style = \"background-color: #97c4f5; border-radius: 5px;\">&nbsp;Duration&nbsp;</span>&nbsp&nbsp&nbsp&nbsp&nbsp<br>----------------------------------------------------------------------------------------------------<br><br>Admission Date:  [**2115-2-22**]              Discharge Date:   [**2115-3-19**]<br><br>Date of Birth:  [**2078-8-9**]             Sex:   M<br><br>Service: MEDICINE<br><br>Allergies:<br><span style = \"background-color: #aa9cfc; border-radius: 5px;\">&nbsp;Vicodin&nbsp;</span><br><br>Attending:[**First Name3 (LF) 4891**]<br>Chief Complaint:<br>Post-cardiac arrest, asthma exacerbation<br><br>Major Surgical or Invasive Procedure:<br>Intubation<br>Removal of chest tubes placed at an outside hospital<br>R CVL placement<br><br><br>History of Present Illness:<br>Mr. [**Known lastname 3234**] is a 36 year old gentleman with a PMH signifciant<br>with dilated cardiomyopathy s/p AICD, asthma, and HTN admitted<br>to an OSH with dyspnea now admitted to the MICU after PEA arrest<br>x2. The patient initially presented to LGH ED with hypoxemic<br>respiratory distress. While at the OSH, he received <span style = \"background-color: #aa9cfc; border-radius: 5px;\">&nbsp;CTX&nbsp;</span>,<br><span style = \"background-color: #aa9cfc; border-radius: 5px;\">&nbsp;azithromycin&nbsp;</span>, <span style = \"background-color: #ffeb80; border-radius: 5px;\">&nbsp;SC&nbsp;</span> <span style = \"background-color: #aa9cfc; border-radius: 5px;\">&nbsp;epinephrine&nbsp;</span>, and <span style = \"background-color: #aa9cfc; border-radius: 5px;\">&nbsp;solumedrol&nbsp;</span>. While at the OSH,<br>he became confused and subsequently had an episode of PEA arrest<br>and was intubated. He received <span style = \"background-color: #aa9cfc; border-radius: 5px;\">&nbsp;epinephrine&nbsp;</span>, <span style = \"background-color: #aa9cfc; border-radius: 5px;\">&nbsp;atropine&nbsp;</span>, <span style = \"background-color: #aa9cfc; border-radius: 5px;\">&nbsp;magnesium&nbsp;</span>,<br>and <span style = \"background-color: #aa9cfc; border-radius: 5px;\">&nbsp;bicarb&nbsp;</span>. In addition, he had bilateral needle thoracostomies<br>with report of air return on the left, and he subsequently had<br>bilateral chest tubes placed.  After approximately 15-20 minutes<br>of rescucitation, he had ROSC. He received <span style = \"background-color: #aa9cfc; border-radius: 5px;\">&nbsp;vecuronium&nbsp;</span> and was<br>started on an <span style = \"background-color: #aa9cfc; border-radius: 5px;\">&nbsp;epi&nbsp;</span> <span style = \"background-color: #ffeb80; border-radius: 5px;\">&nbsp;gtt&nbsp;</span> for <span style = \"background-color: #e4e7d2; border-radius: 5px;\">&nbsp;asthma&nbsp;</span> and a cooling protocol, and was<br>then transferred to [**Hospital1 18**] for further evaluation. Of note, the<br>patient was admitted to LGH in [**1-4**] for dyspnea, and was<br>subsequently diagnosed with a <span style = \"background-color: #e4e7d2; border-radius: 5px;\">&nbsp;CAP&nbsp;</span> and <span style = \"background-color: #e4e7d2; border-radius: 5px;\">&nbsp;asthma&nbsp;</span> treated with <span style = \"background-color: #aa9cfc; border-radius: 5px;\">&nbsp;CTX&nbsp;</span><br>and <span style = \"background-color: #aa9cfc; border-radius: 5px;\">&nbsp;azithromycin&nbsp;</span>. Per his family, he has also had multiple<br>admissions this winter for asthma exacerbations.<br>.<br>In the [**Hospital1 18**] ED, 35.3 102 133/58 100%AC 500x20, 5, 1.0 with an<br>ABG 7.16/66/162. He had a CTH which was unremarkable. He then<br>had a CTA chest, afterwhich he went into PEA arrest.<br>Rescucitation last approximately 10-15 minutes with multiple<br>rounds of <span style = \"background-color: #aa9cfc; border-radius: 5px;\">&nbsp;epi&nbsp;</span> and <span style = \"background-color: #aa9cfc; border-radius: 5px;\">&nbsp;bicarb&nbsp;</span>, with ROSC. He was then admitted to the<br>MICU for further management.<br>.<br>Currently, the patient is intubated, sedated, and parlyzed.<br><br>Past Medical History:<br>Asthma<br>Dilated cardiomyopathy<br>Multiple admissions for dyspnea this winter ([**1-26**]).<br>Anxiety/depression<br>CKD<br>HLD<br>Obesity<br>HTN<br><br>Social History:<br>Unknown<br><br>Family History:<br>Unknown<br><br>Physical Exam:<br>ADMISSION:<br>VS: 35.9 124 129/67 99% AC 480x24, 5, 1.0<br>Gen: ETT in place, intubated, sedated.<br>HEENT: ETT in place.<br>CV: Tachy S1+S2<br>Pulm: Poor air movement bilaterally. Diffuse wheezes<br>bilaterally.<br>Abd: S/D hypoactive BS<br>Ext: 1+ edema bilaterally<br>Neuro: Unresponsive.<br>.<br>Discharge: 98.5 102/65 76 20 95-98% RA<br>In cage bed to prevent patient from falling out of bed.<br>Occasionally calling out. Lungs clear without wheezes.<br><br><br>Pertinent Results:<br>Labs on Admission:<br>[**2115-2-22**] 08:50AM BLOOD WBC-19.5* RBC-4.76 Hgb-14.9 Hct-44.3<br>MCV-93 MCH-31.4 MCHC-33.7 RDW-12.9 Plt Ct-201<br>[**2115-2-22**] 08:50AM BLOOD PT-14.1* PTT-25.9 INR(PT)-1.2*<br>[**2115-2-22**] 08:50AM BLOOD Glucose-306* UreaN-21* Creat-1.2 Na-144<br>K-4.1 Cl-111* HCO3-28 AnGap-9<br>[**2115-2-22**] 08:50AM BLOOD Albumin-3.4* Calcium-6.2* Phos-5.5*<br>Mg-2.2<br>[**2115-2-22**] 09:32AM BLOOD calTIBC-320 Ferritn-1129* TRF-246<br>[**2115-2-22**] 07:17AM BLOOD Type-ART pO2-162* pCO2-66* pH-7.16*<br>calTCO2-25 Base XS--6 Intubat-INTUBATED<br>.<br>Labs on Discharge<br>[**2115-3-18**] 11:34AM BLOOD Type-ART pO2-95 pCO2-33* pH-7.54*<br>calTCO2-29 Base XS-5 Intubat-NOT INTUBA<br>[**2115-3-5**] 05:35AM BLOOD ALT-49* AST-23 AlkPhos-53 TotBili-0.9<br>[**2115-3-19**] 04:45AM BLOOD Glucose-73 UreaN-25* Creat-1.4* Na-133<br>K-4.1 Cl-95* HCO3-21* AnGap-21*<br>[**2115-3-19**] 04:45AM BLOOD WBC-12.4* RBC-4.47* Hgb-14.3 Hct-41.3<br>MCV-93 MCH-32.0 MCHC-34.6 RDW-13.3 Plt Ct-352<br>[**2115-3-19**] 04:45AM BLOOD Neuts-56 Bands-0 Lymphs-38 Monos-3 Eos-3<br>Baso-0 Atyps-0 Metas-0 Myelos-0<br>.<br>CXR (in MICU): Mr read - cardiomegaly, RIJ in SVC, ETT 4.5 cm<br>above carina. Blunting of costophrenic angles bilaterally with<br>low lung volumes. Loss of retrocardiac diagphragm and bilateral<br>opacities (L>R)<br>.<br>CXR:<br>1. NG tube at 7.2 cm above the carina. [**Month (only) 116**] consider advancing<br>for optimal placement.<br>2. Severe cardiomegaly with globular shape. In the absence of<br>prior<br>comparison, the differential is broad, including moderate<br>pericardial<br>effusion, mediastinal hemorrhage, or acute cardiac failure.<br>Recommend<br>clinical correlation.<br>.<br>CTH: My read, no acute bleed<br>.<br>CTA Chest:<br>1. No evidence of pulmonary embolism, although evaluation of<br>subsegmental branches is limited.<br>2. Moderate cardiomegaly without pericardial effusion.<br>3. Bilateral dependent atelectasis.<br>4. Multiple nondisplaced rib fractures on the right, some of<br>which are subacute. Also possible subtle nondisplaced fractures<br>of the left ribs.<br>5. Nondisplaced acute sternal fracture in addition to a subacute<br>nondisplaced sternal fracture.<br>.<br>TTE: The left atrium is moderately dilated. The estimated right<br>atrial pressure is 10-20mmHg. Left ventricular wall thicknesses<br>are normal. The left ventricular cavity is severely dilated. LV<br>systolic function appears depressed (ejection fraction ? 30<br>percent) with regional variation. There is considerable<br>beat-to-beat variability of the left ventricular ejection<br>fraction due to an irregular rhythm/premature beats. The right<br>ventricular free wall thickness is normal. The right ventricular<br>cavity is dilated with depressed free wall contractility. The<br>aortic root is mildly dilated at the sinus level. The ascending<br>aorta is mildly dilated. The aortic valve leaflets (3) appear<br>structurally normal with good leaflet excursion and no aortic<br>stenosis or aortic regurgitation. The mitral valve leaflets are<br>structurally normal. There is no mitral valve prolapse. Mild<br>(1+) mitral regurgitation is seen. The pulmonary artery systolic<br>pressure could not be determined. There is no pericardial<br>effusion.<br>.<br>ECG (post-arrest):  Sinus with 1:1 conduction. LAA. LAD, RBBB,<br>LAFB. STD in V4-V6.<br>.<br>ECG (pre-arrest): Sinus with 1:1 conduction. LAD, bifascicular<br>block. No lateral STD.<br>.<br>ECG (OSH, unclear pre/post arrest): Sinus with 1:1 conduction.<br>Bifascicular (RBBB, LAFB) block. STD in V5-6.<br>.<br>EEG [**2-27**]<br>IMPRESSION: This is an abnormal video EEG telemetry due to the<br>slow and<br>disorganized background of 6.5 Hz with bursts of generalized<br>slowing<br>that showed no clear reactivity. These findings indicate a<br>severe<br>encephalopathy. This may be consistent with the patient's<br>history of<br>anoxia; however, toxic/metabolic disturbances, infection, and<br>medication<br>effects are also among the most frequent causes of<br>encephalopathy. No<br>clear epileptiform discharges or seizures were seen.<br><br>LUMBAR SPINE [**2115-3-11**]<br><br>CLINICAL INFORMATION: Evidence of fracture, seizure, fall, low<br>back pain.<br><br>FINDINGS:<br><br>Three views of the lumbar spine demonstrate mild narrowing of<br>the left<br>femoroacetabular joint. There is mild scoliosis of the<br>thoracolumbar spine.  The ventricular lead of a pacemaker is<br>identified. No fracture of L2 through L5 is identified. However,<br>there is a compression fracture of L1, with compression of the<br>superior endplate, and a sclerotic fracture line. Given the<br>mechanism of fall, if there is acute pain referable to L1, then<br>this would be considered an acute finding. There is no apparent<br>retropulsion of the posterior margin of L1 into the spinal<br>canal. No other fractures are identified at this time. Facet<br>joints are aligned. There is early calcification of the aorta.<br>IMPRESSION: Compression fracture of L1 with anterior wedge<br>deformity, likely an acute finding. No other fractures<br>identified.<br>EKG: Normal sinus rhythm. Complete right bundle-branch block<br>with left anterior fascicular block. Diffuse ST-T wave changes<br>laterally.<br>CT Head:<br>COMPARISON: [**2115-2-22**].<br>TECHNIQUE: Non-contrast axial images were obtained through the<br>brain.<br>FINDINGS: There is no intracranial hemorrhage, edema, or loss of<br>[**Doctor Last Name 352**]/white matter differentiation. Ventricles and sulci are<br>normal in size and configuration. The basilar cisterns are not<br>compressed. Paranasal sinuses demonstrate fluid in the sphenoid<br>air cells and right posterior ethmoid air cell, likely related<br>to prolonged hospitalization.  Mastoid air cells are well<br>aerated.<br>IMPRESSION: No evidence of acute intracranial abnormalities.<br><br><br>Brief Hospital Course:<br>Mr. [**Known lastname 3234**] is a 36 year old gentleman with a PMH signifciant<br>with dilated cardiomyopathy s/p AICD, PE not on anticoagulation,<br>asthma, and HTN admitted to an OSH with dyspnea now the<br>transferred to [**Hospital1 18**] MICU after PEA arrest x2.<br><br># PEA arrest and subsequent anoxic brain injury.: Suspect that<br>original OSH PEA arrest due to hypoxemia or acidosis, with [**Hospital1 18**]<br>ED PEA arrest due to acidosis with admission pH 7.16 on arrival.<br> TTE with evidence of RV failure to suggest PE. LVEF 30% with<br>known dilated cardiomyopathy. He was cooled per protocol.<br>Initially, his EEG was concerning without evident brain<br>activity. On hospital day 3, there was only comatose activity<br>and his prognosis was guarded. However, the patient was able to<br>be weaned off the vent and over the course of the next three<br>days his mental status improved.  He was alert, oriented to<br>place and day of the week and moving all 4 extremities.  He<br>became more interactive on transfer to the floor, was initially<br>speaking in spanish and English and not always making sense but<br>then started responding more appropiately and following<br>commands.  On hospital day 11 he had a witnessed <span style = \"background-color: #e4e7d2; border-radius: 5px;\">&nbsp;grand mal<br>seizure&nbsp;</span> and was given <span style = \"background-color: #aa9cfc; border-radius: 5px;\">&nbsp;ativan&nbsp;</span> and started on <span style = \"background-color: #aa9cfc; border-radius: 5px;\">&nbsp;Keppra&nbsp;</span> with<br>neurology consult.  His mental status was worse for 24 hours<br>after the seizure but then he slowly returned to his recent<br>baseline.  He was somewhat <span style = \"background-color: #e4e7d2; border-radius: 5px;\">&nbsp;aggitated&nbsp;</span> so his <span style = \"background-color: #aa9cfc; border-radius: 5px;\">&nbsp;Keppra&nbsp;</span> was switched<br>to <span style = \"background-color: #aa9cfc; border-radius: 5px;\">&nbsp;Topiramate&nbsp;</span>. He had a subsequent seizure on [**3-18**] with LUE<br>tonic clonic activity and impaired consciousness but this<br>resolved spontaneously after 1-2 minutes. He was contineud on<br><span style = \"background-color: #aa9cfc; border-radius: 5px;\">&nbsp;topamax&nbsp;</span> per neuro recommendations. OT and PT were consulted and<br>worked with the patient as he will likely require a long<br>rehabilitation course.  At the time of discharge the patient was<br>alert, oriented (though not always to date), following commands<br>but impulsive with poor motor planning leading to several falls.<br> Neurology notes indicate the patient has the potential<br>toimprove from a neurologic standpoint. He also may have<br><span style = \"background-color: #e4e7d2; border-radius: 5px;\">&nbsp;recurrent seizures&nbsp;</span> which should be treated with <span style = \"background-color: #aa9cfc; border-radius: 5px;\">&nbsp;ativan&nbsp;</span> <span style = \"background-color: #ffeb80; border-radius: 5px;\">&nbsp;IV&nbsp;</span> or <span style = \"background-color: #ffeb80; border-radius: 5px;\">&nbsp;IM&nbsp;</span><br>and do not neccessarily indicate patient needs to return to<br>hospital unless they continue for greater than 5 minutes or he<br>has multiple recurrent seizures or complications such as<br>aspiration.<br>-patient will be on <span style = \"background-color: #aa9cfc; border-radius: 5px;\">&nbsp;Topiramate&nbsp;</span> <span style = \"background-color: #ff9561; border-radius: 5px;\">&nbsp;25mg&nbsp;</span> <span style = \"background-color: #ffeb80; border-radius: 5px;\">&nbsp;PO&nbsp;</span> <span style = \"background-color: #9cc9cc; border-radius: 5px;\">&nbsp;BID&nbsp;</span> until [**3-22**] <span style = \"background-color: #97c4f5; border-radius: 5px;\">&nbsp;PM&nbsp;</span> then<br>increase to <span style = \"background-color: #ff9561; border-radius: 5px;\">&nbsp;50mg&nbsp;</span> <span style = \"background-color: #ffeb80; border-radius: 5px;\">&nbsp;po&nbsp;</span> <span style = \"background-color: #9cc9cc; border-radius: 5px;\">&nbsp;BID&nbsp;</span> <span style = \"background-color: #97c4f5; border-radius: 5px;\">&nbsp;for seven days&nbsp;</span> then increase to <span style = \"background-color: #ff9561; border-radius: 5px;\">&nbsp;75mg&nbsp;</span> [**Hospital1 **]<br><span style = \"background-color: #9cc9cc; border-radius: 5px;\">&nbsp;ongoing&nbsp;</span>.<br>-patient will follow up with Dr. [**Last Name (STitle) **] [**Name (STitle) **] in his s/p<br>arrest neurology clinic<br>-patient will require intensive PT and OT in an anoxic brain<br>injury unit.<br>.<br># Respiratory failure: Believed to be due to status asthmaticus,<br>although inciting event unclear. [**Name2 (NI) 227**] multiple cardiac arrests,<br>also a concern for development of ARDS.  The patient was<br>initially treated broadly with <span style = \"background-color: #aa9cfc; border-radius: 5px;\">&nbsp;vancomycin&nbsp;</span>, <span style = \"background-color: #aa9cfc; border-radius: 5px;\">&nbsp;cefepime&nbsp;</span>, <span style = \"background-color: #aa9cfc; border-radius: 5px;\">&nbsp;flagyl&nbsp;</span>,<br><span style = \"background-color: #aa9cfc; border-radius: 5px;\">&nbsp;cipro&nbsp;</span>, and <span style = \"background-color: #aa9cfc; border-radius: 5px;\">&nbsp;oseltamavir&nbsp;</span>. He was treated with <span style = \"background-color: #ffeb80; border-radius: 5px;\">&nbsp;IV&nbsp;</span> <span style = \"background-color: #aa9cfc; border-radius: 5px;\">&nbsp;soludemedrol&nbsp;</span> and<br><span style = \"background-color: #aa9cfc; border-radius: 5px;\">&nbsp;albuterol&nbsp;</span> <span style = \"background-color: #7aecec; border-radius: 5px;\">&nbsp;MDI&nbsp;</span>. He was ventialted according to ARDS-Net protocol.<br>On admission, he had two chest tubes placed for pneumothoraces.<br>They were removed on hospital day 1. In his first several days,<br>his respiratory status was comprimised by lobar collapse, first<br>of the RUL and then of the RML. His extubation was initially<br>limited both by <span style = \"background-color: #e4e7d2; border-radius: 5px;\">&nbsp;agitation&nbsp;</span> requiring <span style = \"background-color: #aa9cfc; border-radius: 5px;\">&nbsp;sedation&nbsp;</span> and by requirements<br>for high PEEP to maintain oxygenation. His oxygenation was<br>improved with diuresis and <span style = \"background-color: #e4e7d2; border-radius: 5px;\">&nbsp;agitation&nbsp;</span> was better controlled with<br><span style = \"background-color: #aa9cfc; border-radius: 5px;\">&nbsp;seroquel&nbsp;</span>. He was extubated on [**3-1**] and respiratory status was<br>stable.  His <span style = \"background-color: #e4e7d2; border-radius: 5px;\">&nbsp;Asthma&nbsp;</span> was treated with <span style = \"background-color: #97c4f5; border-radius: 5px;\">&nbsp;standing&nbsp;</span> and <span style = \"background-color: #97c4f5; border-radius: 5px;\">&nbsp;PRN&nbsp;</span> <span style = \"background-color: #aa9cfc; border-radius: 5px;\">&nbsp;albuterol&nbsp;</span><br>and <span style = \"background-color: #aa9cfc; border-radius: 5px;\">&nbsp;ipratriopium&nbsp;</span> and a slow <span style = \"background-color: #aa9cfc; border-radius: 5px;\">&nbsp;prednisone&nbsp;</span> <span style = \"background-color: #bfe1d9; border-radius: 5px;\">&nbsp;taper&nbsp;</span> which he l<br>completed on [**2115-3-18**] and he was restarted on <span style = \"background-color: #aa9cfc; border-radius: 5px;\">&nbsp;Advair&nbsp;</span><br>-patient may require additional nebs on top of his <span style = \"background-color: #97c4f5; border-radius: 5px;\">&nbsp;standing&nbsp;</span><br><span style = \"background-color: #aa9cfc; border-radius: 5px;\">&nbsp;advair&nbsp;</span> though his respiratory status has been very stable,<br>without <span style = \"background-color: #e4e7d2; border-radius: 5px;\">&nbsp;wheezing&nbsp;</span> for the last week.<br>- would like benefit from outpatient PFTs and is scheduled to<br>see a pulmonologist in follow up.<br>.<br># <span style = \"background-color: #e4e7d2; border-radius: 5px;\">&nbsp;Ventilator associated pneumonia&nbsp;</span>:  Patient developed a fever on<br>[**2-27**] with new infiltrates on chest xray while intubated. He was<br>initially covered with <span style = \"background-color: #aa9cfc; border-radius: 5px;\">&nbsp;vanc&nbsp;</span>/<span style = \"background-color: #aa9cfc; border-radius: 5px;\">&nbsp;cefepime&nbsp;</span> and <span style = \"background-color: #aa9cfc; border-radius: 5px;\">&nbsp;cipro&nbsp;</span>. <span style = \"background-color: #aa9cfc; border-radius: 5px;\">&nbsp;Cipro&nbsp;</span> was<br>eventually discontinued. He did not grow any organisms other<br>than yeast in his sputum. He completed an <span style = \"background-color: #97c4f5; border-radius: 5px;\">&nbsp;8 day&nbsp;</span> course of<br><span style = \"background-color: #aa9cfc; border-radius: 5px;\">&nbsp;Vanco&nbsp;</span>/<span style = \"background-color: #aa9cfc; border-radius: 5px;\">&nbsp;Cefepime&nbsp;</span>.<br>.<br># Myoclonus: when mental status improved, was noted to have<br>myoclonic jerks. per neurology, likely [**First Name8 (NamePattern2) **] [**Last Name (NamePattern1) 1683**] Syndrome<br>which is anoxic injury to the purkinje cells.  These jerks<br>continued for about one week and then became rare.<br>.<br># dilated [**Last Name (LF) 89982**], [**First Name3 (LF) **] 30%. s/p ICD.  Patient was<br><span style = \"background-color: #e4e7d2; border-radius: 5px;\">&nbsp;diuresed&nbsp;</span> with <span style = \"background-color: #ffeb80; border-radius: 5px;\">&nbsp;IV&nbsp;</span> <span style = \"background-color: #aa9cfc; border-radius: 5px;\">&nbsp;lasix&nbsp;</span> in the ED and then transitioned to <span style = \"background-color: #ffeb80; border-radius: 5px;\">&nbsp;PO&nbsp;</span><br><span style = \"background-color: #aa9cfc; border-radius: 5px;\">&nbsp;lasix&nbsp;</span>, <span style = \"background-color: #bfe1d9; border-radius: 5px;\">&nbsp;home dose&nbsp;</span>, on the floor.  His respiratory status remained<br>stable. Also continued on <span style = \"background-color: #bfe1d9; border-radius: 5px;\">&nbsp;home dose&nbsp;</span> of <span style = \"background-color: #aa9cfc; border-radius: 5px;\">&nbsp;carvedilol&nbsp;</span> and <span style = \"background-color: #aa9cfc; border-radius: 5px;\">&nbsp;Lisinopril&nbsp;</span><br>but <span style = \"background-color: #aa9cfc; border-radius: 5px;\">&nbsp;ACE&nbsp;</span> downtitrated from <span style = \"background-color: #ff9561; border-radius: 5px;\">&nbsp;40&nbsp;</span> to <span style = \"background-color: #ff9561; border-radius: 5px;\">&nbsp;20&nbsp;</span> when had <span style = \"background-color: #e4e7d2; border-radius: 5px;\">&nbsp;elevated Cr 1.9&nbsp;</span> on<br>[**3-18**] and slightly <span style = \"background-color: #e4e7d2; border-radius: 5px;\">&nbsp;low BPs&nbsp;</span> high 90s/60s. BP improved to 100s/60s.<br><br>.<br>#<span style = \"background-color: #e4e7d2; border-radius: 5px;\">&nbsp;Hypertension&nbsp;</span>: Patient's home regimen was continued on the<br>floor, but his SBP dipped into the high 80s and low 90s so<br><span style = \"background-color: #aa9cfc; border-radius: 5px;\">&nbsp;lisinopril&nbsp;</span> was decreased to <span style = \"background-color: #ff9561; border-radius: 5px;\">&nbsp;20mg&nbsp;</span> <span style = \"background-color: #ffeb80; border-radius: 5px;\">&nbsp;po&nbsp;</span> <span style = \"background-color: #9cc9cc; border-radius: 5px;\">&nbsp;daily&nbsp;</span> and his SBP remained<br>100-130.<br>.<br># L1 compression fracture: After the patient fell, he was<br>complaining of low back pain so a L-spine Xray was performed and<br>showed L1 compressin fracture with No cord impingement on<br>imaging.  The patient had no localizing deficits on serial neuro<br>exam.  He was treated with <span style = \"background-color: #e4e7d2; border-radius: 5px;\">&nbsp;pain&nbsp;</span> medication including <span style = \"background-color: #bfe1d9; border-radius: 5px;\">&nbsp;low dose&nbsp;</span><br><span style = \"background-color: #aa9cfc; border-radius: 5px;\">&nbsp;ultram&nbsp;</span>, <span style = \"background-color: #97c4f5; border-radius: 5px;\">&nbsp;standing&nbsp;</span> <span style = \"background-color: #aa9cfc; border-radius: 5px;\">&nbsp;tylenol&nbsp;</span> and a <span style = \"background-color: #aa9cfc; border-radius: 5px;\">&nbsp;lidocaine&nbsp;</span> <span style = \"background-color: #7aecec; border-radius: 5px;\">&nbsp;patch&nbsp;</span>.  <span style = \"background-color: #aa9cfc; border-radius: 5px;\">&nbsp;Calcitonin&nbsp;</span> was<br>tried for <span style = \"background-color: #e4e7d2; border-radius: 5px;\">&nbsp;pain&nbsp;</span> with compression fracture but this did not seem<br>to help with symptoms so was discontinued.<br>.<br># Leukocytosis: WBC >20  persistently in the MICU even after<br>being treated for infection.  Since no new infection was found<br>this was presumed [**12-26**] <span style = \"background-color: #aa9cfc; border-radius: 5px;\">&nbsp;steroids&nbsp;</span> and the <span style = \"background-color: #ff8197; border-radius: 5px;\">&nbsp;leukocytosis&nbsp;</span> improved<br>with <span style = \"background-color: #aa9cfc; border-radius: 5px;\">&nbsp;prednisone&nbsp;</span> taper.  WBC 12 on day of discharge<br>.<br># <span style = \"background-color: #ff8197; border-radius: 5px;\">&nbsp;Hyperglycemia&nbsp;</span>: Patient is not known to be a diabetic and was<br>felt [**12-26**] <span style = \"background-color: #aa9cfc; border-radius: 5px;\">&nbsp;steroids&nbsp;</span>,  his sugars were controlled on <span style = \"background-color: #bfe1d9; border-radius: 5px;\">&nbsp;sliding scale&nbsp;</span><br><span style = \"background-color: #aa9cfc; border-radius: 5px;\">&nbsp;insulin&nbsp;</span> in the hospital but he no longer had <span style = \"background-color: #aa9cfc; border-radius: 5px;\">&nbsp;insulin&nbsp;</span><br>requirements as his <span style = \"background-color: #aa9cfc; border-radius: 5px;\">&nbsp;prednisone&nbsp;</span> was tapered.<br>.<br>#. [**Last Name (un) **]: Cr 1.9 on [**3-18**] from 1.2 which improved to 1.4 on [**3-19**]<br>with decreasing <span style = \"background-color: #aa9cfc; border-radius: 5px;\">&nbsp;ACE&nbsp;</span> and 500cc bolus. He should have repeat<br>creatinine and labs on [**3-22**] to ensure stability.<br><br># Guardianship: Guardianship paperwork was started in the<br>hospital.<br><br>Medications on Admission:<br><span style = \"background-color: #aa9cfc; border-radius: 5px;\">&nbsp;Carvedilol&nbsp;</span> <span style = \"background-color: #ff9561; border-radius: 5px;\">&nbsp;25&nbsp;</span> [**Hospital1 **]<br><span style = \"background-color: #aa9cfc; border-radius: 5px;\">&nbsp;Lasix&nbsp;</span> <span style = \"background-color: #ff9561; border-radius: 5px;\">&nbsp;80 mg&nbsp;</span> <span style = \"background-color: #ffeb80; border-radius: 5px;\">&nbsp;po&nbsp;</span> <span style = \"background-color: #9cc9cc; border-radius: 5px;\">&nbsp;bid&nbsp;</span><br><span style = \"background-color: #aa9cfc; border-radius: 5px;\">&nbsp;Xanax&nbsp;</span> <span style = \"background-color: #ff9561; border-radius: 5px;\">&nbsp;0.25 mg&nbsp;</span> <span style = \"background-color: #bfe1d9; border-radius: 5px;\">&nbsp;1-2&nbsp;</span> <span style = \"background-color: #7aecec; border-radius: 5px;\">&nbsp;tabs&nbsp;</span> <span style = \"background-color: #97c4f5; border-radius: 5px;\">&nbsp;prn&nbsp;</span><br><span style = \"background-color: #aa9cfc; border-radius: 5px;\">&nbsp;albuterol&nbsp;</span> <span style = \"background-color: #7aecec; border-radius: 5px;\">&nbsp;MDI&nbsp;</span><br><span style = \"background-color: #aa9cfc; border-radius: 5px;\">&nbsp;Ibuprofen&nbsp;</span> <span style = \"background-color: #97c4f5; border-radius: 5px;\">&nbsp;prn&nbsp;</span><br><span style = \"background-color: #aa9cfc; border-radius: 5px;\">&nbsp;Benadryl&nbsp;</span> <span style = \"background-color: #97c4f5; border-radius: 5px;\">&nbsp;prn&nbsp;</span><br><span style = \"background-color: #aa9cfc; border-radius: 5px;\">&nbsp;Advair&nbsp;</span> <span style = \"background-color: #7aecec; border-radius: 5px;\">&nbsp;diskus&nbsp;</span><br><span style = \"background-color: #aa9cfc; border-radius: 5px;\">&nbsp;Lsinopril&nbsp;</span> <span style = \"background-color: #ff9561; border-radius: 5px;\">&nbsp;40&nbsp;</span> <span style = \"background-color: #9cc9cc; border-radius: 5px;\">&nbsp;daily&nbsp;</span><br><br>Discharge Medications:<br>1. <span style = \"background-color: #aa9cfc; border-radius: 5px;\">&nbsp;bisacodyl&nbsp;</span> <span style = \"background-color: #ff9561; border-radius: 5px;\">&nbsp;5 mg&nbsp;</span> <span style = \"background-color: #7aecec; border-radius: 5px;\">&nbsp;Tablet&nbsp;</span>, <span style = \"background-color: #97c4f5; border-radius: 5px;\">&nbsp;Delayed Release&nbsp;</span> (E.C.) Sig: <span style = \"background-color: #bfe1d9; border-radius: 5px;\">&nbsp;Two (2)&nbsp;</span><br><span style = \"background-color: #7aecec; border-radius: 5px;\">&nbsp;Tablet&nbsp;</span>, <span style = \"background-color: #97c4f5; border-radius: 5px;\">&nbsp;Delayed Release&nbsp;</span> (E.C.) <span style = \"background-color: #ffeb80; border-radius: 5px;\">&nbsp;PO&nbsp;</span> <span style = \"background-color: #9cc9cc; border-radius: 5px;\">&nbsp;DAILY&nbsp;</span> (Daily) <span style = \"background-color: #9cc9cc; border-radius: 5px;\">&nbsp;as needed&nbsp;</span> for<br><span style = \"background-color: #e4e7d2; border-radius: 5px;\">&nbsp;Constipation&nbsp;</span>.<br>2. <span style = \"background-color: #aa9cfc; border-radius: 5px;\">&nbsp;senna&nbsp;</span> <span style = \"background-color: #ff9561; border-radius: 5px;\">&nbsp;8.6 mg&nbsp;</span> <span style = \"background-color: #7aecec; border-radius: 5px;\">&nbsp;Tablet&nbsp;</span> Sig: <span style = \"background-color: #bfe1d9; border-radius: 5px;\">&nbsp;One (1)&nbsp;</span> <span style = \"background-color: #7aecec; border-radius: 5px;\">&nbsp;Tablet&nbsp;</span> <span style = \"background-color: #ffeb80; border-radius: 5px;\">&nbsp;PO&nbsp;</span> <span style = \"background-color: #9cc9cc; border-radius: 5px;\">&nbsp;BID (2 times a<br>day) as needed&nbsp;</span> for <span style = \"background-color: #e4e7d2; border-radius: 5px;\">&nbsp;Constipation&nbsp;</span>.<br>3. <span style = \"background-color: #aa9cfc; border-radius: 5px;\">&nbsp;acetaminophen&nbsp;</span> <span style = \"background-color: #ff9561; border-radius: 5px;\">&nbsp;325 mg&nbsp;</span> <span style = \"background-color: #7aecec; border-radius: 5px;\">&nbsp;Tablet&nbsp;</span> Sig: <span style = \"background-color: #bfe1d9; border-radius: 5px;\">&nbsp;Two (2)&nbsp;</span> <span style = \"background-color: #7aecec; border-radius: 5px;\">&nbsp;Tablet&nbsp;</span> <span style = \"background-color: #ffeb80; border-radius: 5px;\">&nbsp;PO&nbsp;</span> <span style = \"background-color: #9cc9cc; border-radius: 5px;\">&nbsp;Q6H (every<br>6 hours) as needed&nbsp;</span> for <span style = \"background-color: #e4e7d2; border-radius: 5px;\">&nbsp;pain&nbsp;</span>/<span style = \"background-color: #e4e7d2; border-radius: 5px;\">&nbsp;fever&nbsp;</span>.<br>4. <span style = \"background-color: #aa9cfc; border-radius: 5px;\">&nbsp;carvedilol&nbsp;</span> <span style = \"background-color: #ff9561; border-radius: 5px;\">&nbsp;12.5 mg&nbsp;</span> <span style = \"background-color: #7aecec; border-radius: 5px;\">&nbsp;Tablet&nbsp;</span> Sig: <span style = \"background-color: #bfe1d9; border-radius: 5px;\">&nbsp;Two (2)&nbsp;</span> <span style = \"background-color: #7aecec; border-radius: 5px;\">&nbsp;Tablet&nbsp;</span> <span style = \"background-color: #ffeb80; border-radius: 5px;\">&nbsp;PO&nbsp;</span> <span style = \"background-color: #9cc9cc; border-radius: 5px;\">&nbsp;BID (2 times<br>a day).&nbsp;</span><br>5. <span style = \"background-color: #aa9cfc; border-radius: 5px;\">&nbsp;docusate sodium&nbsp;</span> <span style = \"background-color: #ff9561; border-radius: 5px;\">&nbsp;100 mg&nbsp;</span> <span style = \"background-color: #7aecec; border-radius: 5px;\">&nbsp;Capsule&nbsp;</span> Sig: <span style = \"background-color: #bfe1d9; border-radius: 5px;\">&nbsp;One (1)&nbsp;</span> <span style = \"background-color: #7aecec; border-radius: 5px;\">&nbsp;Capsule&nbsp;</span> <span style = \"background-color: #ffeb80; border-radius: 5px;\">&nbsp;PO&nbsp;</span> BID (2<br>times a day).<br>6. <span style = \"background-color: #aa9cfc; border-radius: 5px;\">&nbsp;furosemide&nbsp;</span> <span style = \"background-color: #ff9561; border-radius: 5px;\">&nbsp;40 mg&nbsp;</span> <span style = \"background-color: #7aecec; border-radius: 5px;\">&nbsp;Tablet&nbsp;</span> Sig: <span style = \"background-color: #bfe1d9; border-radius: 5px;\">&nbsp;Two (2)&nbsp;</span> <span style = \"background-color: #7aecec; border-radius: 5px;\">&nbsp;Tablet&nbsp;</span> <span style = \"background-color: #ffeb80; border-radius: 5px;\">&nbsp;PO&nbsp;</span> <span style = \"background-color: #9cc9cc; border-radius: 5px;\">&nbsp;BID (2 times a<br>day)&nbsp;</span>.<br>7. <span style = \"background-color: #aa9cfc; border-radius: 5px;\">&nbsp;lisinopril&nbsp;</span> <span style = \"background-color: #ff9561; border-radius: 5px;\">&nbsp;10 mg&nbsp;</span> <span style = \"background-color: #7aecec; border-radius: 5px;\">&nbsp;Tablet&nbsp;</span> Sig: <span style = \"background-color: #bfe1d9; border-radius: 5px;\">&nbsp;Two (2)&nbsp;</span> <span style = \"background-color: #7aecec; border-radius: 5px;\">&nbsp;Tablet&nbsp;</span> <span style = \"background-color: #ffeb80; border-radius: 5px;\">&nbsp;PO&nbsp;</span> <span style = \"background-color: #9cc9cc; border-radius: 5px;\">&nbsp;DAILY (Daily)&nbsp;</span>.<br><br>8. <span style = \"background-color: #aa9cfc; border-radius: 5px;\">&nbsp;olanzapine&nbsp;</span> <span style = \"background-color: #ff9561; border-radius: 5px;\">&nbsp;5 mg&nbsp;</span> <span style = \"background-color: #7aecec; border-radius: 5px;\">&nbsp;Tablet, Rapid Dissolve&nbsp;</span> Sig: [**11-25**] <span style = \"background-color: #7aecec; border-radius: 5px;\">&nbsp;Tablet, Rapid<br>Dissolves&nbsp;</span> <span style = \"background-color: #ffeb80; border-radius: 5px;\">&nbsp;PO&nbsp;</span> <span style = \"background-color: #9cc9cc; border-radius: 5px;\">&nbsp;QHS (once a day (at bedtime)) as needed&nbsp;</span> for <span style = \"background-color: #e4e7d2; border-radius: 5px;\">&nbsp;sleep&nbsp;</span>.<br><br>9. <span style = \"background-color: #aa9cfc; border-radius: 5px;\">&nbsp;calcium carbonate&nbsp;</span> <span style = \"background-color: #ff9561; border-radius: 5px;\">&nbsp;200 mg (500 mg)&nbsp;</span> <span style = \"background-color: #7aecec; border-radius: 5px;\">&nbsp;Tablet, Chewable&nbsp;</span> Sig: <span style = \"background-color: #bfe1d9; border-radius: 5px;\">&nbsp;One<br>(1)&nbsp;</span> <span style = \"background-color: #7aecec; border-radius: 5px;\">&nbsp;Tablet, Chewable&nbsp;</span> <span style = \"background-color: #ffeb80; border-radius: 5px;\">&nbsp;PO&nbsp;</span> <span style = \"background-color: #9cc9cc; border-radius: 5px;\">&nbsp;BID (2 times a day)&nbsp;</span>.<br>10. <span style = \"background-color: #aa9cfc; border-radius: 5px;\">&nbsp;cholecalciferol&nbsp;</span> (vitamin D3) <span style = \"background-color: #ff9561; border-radius: 5px;\">&nbsp;400 unit&nbsp;</span> <span style = \"background-color: #7aecec; border-radius: 5px;\">&nbsp;Tablet&nbsp;</span> Sig: <span style = \"background-color: #bfe1d9; border-radius: 5px;\">&nbsp;One (1)&nbsp;</span><br><span style = \"background-color: #7aecec; border-radius: 5px;\">&nbsp;Tablet&nbsp;</span> <span style = \"background-color: #ffeb80; border-radius: 5px;\">&nbsp;PO&nbsp;</span> <span style = \"background-color: #9cc9cc; border-radius: 5px;\">&nbsp;DAILY&nbsp;</span> (Daily).<br>11. <span style = \"background-color: #aa9cfc; border-radius: 5px;\">&nbsp;acetaminophen&nbsp;</span> <span style = \"background-color: #ff9561; border-radius: 5px;\">&nbsp;500 mg&nbsp;</span> <span style = \"background-color: #7aecec; border-radius: 5px;\">&nbsp;Tablet&nbsp;</span> Sig: <span style = \"background-color: #bfe1d9; border-radius: 5px;\">&nbsp;Two (2)&nbsp;</span> <span style = \"background-color: #7aecec; border-radius: 5px;\">&nbsp;Tablet&nbsp;</span> <span style = \"background-color: #ffeb80; border-radius: 5px;\">&nbsp;PO&nbsp;</span> <span style = \"background-color: #9cc9cc; border-radius: 5px;\">&nbsp;TID&nbsp;</span> (3<br>times a day) <span style = \"background-color: #9cc9cc; border-radius: 5px;\">&nbsp;as needed&nbsp;</span> for <span style = \"background-color: #e4e7d2; border-radius: 5px;\">&nbsp;pain&nbsp;</span>/<span style = \"background-color: #e4e7d2; border-radius: 5px;\">&nbsp;fever&nbsp;</span>.<br>12. <span style = \"background-color: #aa9cfc; border-radius: 5px;\">&nbsp;lidocaine&nbsp;</span> <span style = \"background-color: #ff9561; border-radius: 5px;\">&nbsp;5 %(700 mg/patch)&nbsp;</span> <span style = \"background-color: #7aecec; border-radius: 5px;\">&nbsp;Adhesive Patch, Medicated&nbsp;</span> Sig:<br><span style = \"background-color: #bfe1d9; border-radius: 5px;\">&nbsp;One (1)&nbsp;</span> <span style = \"background-color: #7aecec; border-radius: 5px;\">&nbsp;Adhesive Patch, Medicated&nbsp;</span> <span style = \"background-color: #ffeb80; border-radius: 5px;\">&nbsp;Topical&nbsp;</span> <span style = \"background-color: #9cc9cc; border-radius: 5px;\">&nbsp;DAILY&nbsp;</span> (Daily): <span style = \"background-color: #9cc9cc; border-radius: 5px;\">&nbsp;12<br>hours on and 12 hours off&nbsp;</span> every <span style = \"background-color: #9cc9cc; border-radius: 5px;\">&nbsp;24 hour period&nbsp;</span>.<br>13. <span style = \"background-color: #aa9cfc; border-radius: 5px;\">&nbsp;ipratropium bromide&nbsp;</span> <span style = \"background-color: #ff9561; border-radius: 5px;\">&nbsp;0.02&nbsp;</span> % <span style = \"background-color: #7aecec; border-radius: 5px;\">&nbsp;Solution&nbsp;</span> Sig: <span style = \"background-color: #bfe1d9; border-radius: 5px;\">&nbsp;One (1)&nbsp;</span> <span style = \"background-color: #7aecec; border-radius: 5px;\">&nbsp;neb&nbsp;</span><br><span style = \"background-color: #ffeb80; border-radius: 5px;\">&nbsp;Inhalation&nbsp;</span> <span style = \"background-color: #9cc9cc; border-radius: 5px;\">&nbsp;every six (6) hours&nbsp;</span>.<br>14. <span style = \"background-color: #aa9cfc; border-radius: 5px;\">&nbsp;albuterol sulfate&nbsp;</span> <span style = \"background-color: #ff9561; border-radius: 5px;\">&nbsp;2.5 mg /3 mL (0.083 %)&nbsp;</span> <span style = \"background-color: #7aecec; border-radius: 5px;\">&nbsp;Solution&nbsp;</span> for<br><span style = \"background-color: #ffeb80; border-radius: 5px;\">&nbsp;Nebulization&nbsp;</span> Sig: <span style = \"background-color: #bfe1d9; border-radius: 5px;\">&nbsp;One (1)&nbsp;</span> <span style = \"background-color: #7aecec; border-radius: 5px;\">&nbsp;neb&nbsp;</span> <span style = \"background-color: #ffeb80; border-radius: 5px;\">&nbsp;Inhalation&nbsp;</span> <span style = \"background-color: #9cc9cc; border-radius: 5px;\">&nbsp;every six (6) hours&nbsp;</span>.<br>15. <span style = \"background-color: #aa9cfc; border-radius: 5px;\">&nbsp;albuterol sulfate&nbsp;</span> <span style = \"background-color: #ff9561; border-radius: 5px;\">&nbsp;2.5 mg /3 mL (0.083 %)&nbsp;</span> <span style = \"background-color: #7aecec; border-radius: 5px;\">&nbsp;Solution&nbsp;</span> for<br><span style = \"background-color: #ffeb80; border-radius: 5px;\">&nbsp;Nebulization&nbsp;</span> Sig: <span style = \"background-color: #bfe1d9; border-radius: 5px;\">&nbsp;One (1)&nbsp;</span> <span style = \"background-color: #7aecec; border-radius: 5px;\">&nbsp;neb&nbsp;</span> <span style = \"background-color: #ffeb80; border-radius: 5px;\">&nbsp;Inhalation&nbsp;</span> <span style = \"background-color: #9cc9cc; border-radius: 5px;\">&nbsp;Q2H (every 2 hours) as<br>needed&nbsp;</span> for <span style = \"background-color: #e4e7d2; border-radius: 5px;\">&nbsp;SOB&nbsp;</span>.<br>16. <span style = \"background-color: #aa9cfc; border-radius: 5px;\">&nbsp;topiramate&nbsp;</span> <span style = \"background-color: #ff9561; border-radius: 5px;\">&nbsp;25 mg&nbsp;</span> <span style = \"background-color: #7aecec; border-radius: 5px;\">&nbsp;Tablet&nbsp;</span> Sig: <span style = \"background-color: #bfe1d9; border-radius: 5px;\">&nbsp;One (1)&nbsp;</span> <span style = \"background-color: #7aecec; border-radius: 5px;\">&nbsp;Tablet&nbsp;</span> <span style = \"background-color: #ffeb80; border-radius: 5px;\">&nbsp;PO&nbsp;</span> <span style = \"background-color: #9cc9cc; border-radius: 5px;\">&nbsp;BID (2 times<br>a day)&nbsp;</span> <span style = \"background-color: #97c4f5; border-radius: 5px;\">&nbsp;for 3 days&nbsp;</span>: 1 [**Hospital1 **] until [**3-22**] PM then increase to <span style = \"background-color: #bfe1d9; border-radius: 5px;\">&nbsp;2&nbsp;</span><br><span style = \"background-color: #7aecec; border-radius: 5px;\">&nbsp;tablets&nbsp;</span> [**Hospital1 **] <span style = \"background-color: #97c4f5; border-radius: 5px;\">&nbsp;for 7 days&nbsp;</span> then <span style = \"background-color: #bfe1d9; border-radius: 5px;\">&nbsp;3&nbsp;</span> <span style = \"background-color: #7aecec; border-radius: 5px;\">&nbsp;tablets&nbsp;</span> [**Hospital1 **] <span style = \"background-color: #9cc9cc; border-radius: 5px;\">&nbsp;ongoing&nbsp;</span>.<br>17. <span style = \"background-color: #aa9cfc; border-radius: 5px;\">&nbsp;tramadol&nbsp;</span> <span style = \"background-color: #ff9561; border-radius: 5px;\">&nbsp;50 mg&nbsp;</span> <span style = \"background-color: #7aecec; border-radius: 5px;\">&nbsp;Tablet&nbsp;</span> Sig: <span style = \"background-color: #bfe1d9; border-radius: 5px;\">&nbsp;One (1)&nbsp;</span> <span style = \"background-color: #7aecec; border-radius: 5px;\">&nbsp;Tablet&nbsp;</span> <span style = \"background-color: #ffeb80; border-radius: 5px;\">&nbsp;PO&nbsp;</span> <span style = \"background-color: #9cc9cc; border-radius: 5px;\">&nbsp;Q6H (every 6<br>hours) as needed&nbsp;</span> for <span style = \"background-color: #e4e7d2; border-radius: 5px;\">&nbsp;back pain&nbsp;</span>.<br>18. <span style = \"background-color: #aa9cfc; border-radius: 5px;\">&nbsp;fluticasone-salmeterol&nbsp;</span> <span style = \"background-color: #ff9561; border-radius: 5px;\">&nbsp;250-50 mcg/dose&nbsp;</span> <span style = \"background-color: #7aecec; border-radius: 5px;\">&nbsp;Disk with Device&nbsp;</span> Sig:<br><span style = \"background-color: #bfe1d9; border-radius: 5px;\">&nbsp;One (1)&nbsp;</span> <span style = \"background-color: #7aecec; border-radius: 5px;\">&nbsp;inh&nbsp;</span> <span style = \"background-color: #ffeb80; border-radius: 5px;\">&nbsp;Inhalation&nbsp;</span> [**Hospital1 **] <span style = \"background-color: #9cc9cc; border-radius: 5px;\">&nbsp;(2 times a day&nbsp;</span>).<br>19. <span style = \"background-color: #aa9cfc; border-radius: 5px;\">&nbsp;lorazepam&nbsp;</span> <span style = \"background-color: #ff9561; border-radius: 5px;\">&nbsp;2 mg/mL&nbsp;</span> <span style = \"background-color: #7aecec; border-radius: 5px;\">&nbsp;Syringe&nbsp;</span> Sig: <span style = \"background-color: #bfe1d9; border-radius: 5px;\">&nbsp;1-2 mg&nbsp;</span> <span style = \"background-color: #ffeb80; border-radius: 5px;\">&nbsp;Injection&nbsp;</span> <span style = \"background-color: #9cc9cc; border-radius: 5px;\">&nbsp;twice a day<br>as needed&nbsp;</span> for <span style = \"background-color: #e4e7d2; border-radius: 5px;\">&nbsp;seizure&nbsp;</span> that last <span style = \"background-color: #e4e7d2; border-radius: 5px;\">&nbsp;longer than 5 minutes&nbsp;</span>.<br><br><br>Discharge Disposition:<br>Extended Care<br><br>Facility:<br>[**Hospital6 979**] - [**Location (un) 246**]<br><br>Discharge Diagnosis:<br>Anoxic Brain Injury s/p PEA arrest x2<br>Status Asthmaticus<br>Ventilator Associated Pneumonia<br>Chronic Systolic Heart Failure<br>L1 compression fracture<br>Seizures after hypoxic brain injury<br><br><br>Discharge Condition:<br>Mental Status: Confused - sometimes.<br>Level of Consciousness: Alert and interactive.<br>Activity Status: Ambulatory - requires assistance or aid (walker<br>or cane) because he has poor motor planning<br><br><br>Discharge Instructions:<br>You came to the hospital after having a cardiac arrest and an<br>asthma exacerbation.  You had another cardiac arrest in our<br>hospital and were admitted to the MICU.  You required intubation<br>but were able to wean off the machine and breathe on your own.<br>We treated you for pneumonia and asthma.  Your mental status<br>slowly improved, though you did have 2 <span style = \"background-color: #e4e7d2; border-radius: 5px;\">&nbsp;seizures&nbsp;</span>, last on [**3-18**].<br>You were started on<span style = \"background-color: #aa9cfc; border-radius: 5px;\">&nbsp;s eizure medications&nbsp;</span> for this.<br>.<br>Please take your medications as prescribed and follow up with<br>your doctors [**Name5 (PTitle) 7928**].<br><br>Followup Instructions:<br>Department: PULMONARY FUNCTION LAB<br>When: WEDNESDAY [**2115-4-3**] at 1:10 PM<br>With: PULMONARY FUNCTION LAB [**Telephone/Fax (1) 609**]<br>Building: [**Hospital6 29**] [**Location (un) **]<br>Campus: EAST     Best Parking: [**Hospital Ward Name 23**] Garage<br><br>Department: MEDICAL SPECIALTIES<br>When: WEDNESDAY [**2115-4-3**] at 1:30 PM<br>With: DR [**Last Name (STitle) **]/DR [**Last Name (STitle) **] [**Telephone/Fax (1) 612**]<br>Building: SC [**Hospital Ward Name 23**] Clinical Ctr [**Location (un) **]<br>Campus: EAST     Best Parking: [**Hospital Ward Name 23**] Garage<br><br>Department: COGNITIVE NEUROLOGY UNIT<br>When: THURSDAY [**2115-4-11**] at 1 PM<br>With: [**First Name11 (Name Pattern1) **] [**Last Name (NamePattern4) 6403**], MD [**Telephone/Fax (1) 1690**]<br>Building: Ks [**Hospital Ward Name 860**] Building ([**Hospital Ward Name 1826**]/[**Hospital Ward Name 1827**] Complex) [**Location (un) **]<br>Campus: EAST     Best Parking: Main Garage<br><br><br><br>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "utils.display_ehr(data[0].text, data[0].get_entities())\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python [conda env:ehr_nlp]",
   "language": "python",
   "name": "conda-env-ehr_nlp-py"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.8.0"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
